Short Interest in Novozymes A/S (OTCMKTS:NVZMY) Drops By 48.1%

Novozymes A/S (OTCMKTS:NVZMY) saw a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 1,871 shares, a decline of 48.1% from the July 30th total of 3,603 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 38,102 shares, the short-interest ratio is presently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Novozymes A/S stock. Elefante Mark B grew its stake in Novozymes A/S (OTCMKTS:NVZMY) by 73.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent reporting period. Institutional investors own 0.03% of the company’s stock.

Novozymes A/S Price Performance

Shares of OTCMKTS:NVZMY opened at $71.89 on Friday. Novozymes A/S has a one year low of $49.90 and a one year high of $75.27. The stock has a market capitalization of $29.80 billion, a price-to-earnings ratio of 45.50, a PEG ratio of 3.16 and a beta of 0.92. The company has a 50-day simple moving average of $65.12 and a 200-day simple moving average of $61.02. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a current ratio of 1.67.

Novozymes A/S (OTCMKTS:NVZMY) last released its quarterly earnings results on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.16). The company had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Novozymes A/S had a return on equity of 6.60% and a net margin of 14.70%. On average, analysts predict that Novozymes A/S will post 2.47 EPS for the current year.

Wall Street Analysts Forecast Growth

NVZMY has been the subject of several research analyst reports. Kepler Capital Markets raised Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Novozymes A/S currently has a consensus rating of “Buy”.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).